Literature DB >> 15937142

Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.

Clara Brando1, Sunil Mukhopadhyay, Eniko Kovacs, Rosa Medina, Pritesh Patel, Tracey L Catina, Kerry S Campbell, Daniela Santoli.   

Abstract

The major histocompatibility complex nonrestricted cytotoxic leukemic T cell line T acute lymphoblastic leukemia (TALL)-104 is being pursued as a therapeutic agent for cancer. However, the receptors and effector mechanisms responsible for its broad tumoricidal function remain undefined. Here, we examined the roles played by natural cytotoxicity receptors (NCR), killer cell immunoglobulin-like receptors, cytolytic granule components, and tumor necrosis factor (TNF) family members in tumor recognition and lysis by TALL-104 cells. The perforin-granzyme pathway, TNF-related apoptosis-inducing ligand (TRAIL), and Fas were each involved in the lysis of particular tumor targets by TALL-104. Furthermore, phorbol 12-myristate 13-acetate/ionomycin treatment induced surface expression of Fas-L and TRAIL. In addition, supernatants from CD3-stimulated TALL-104 cultures exhibited antiproliferative activity, which was blocked 50-90% by anti-TNF-alpha monoclonal antibody (mAb). Although negative for the NCR natural killer (NK)p44, this cell line was found to express NKp46. An anti-NKp46 antibody strongly blocked TALL-104-mediated lysis of certain targets and directly induced cytokine production, granule release, and redirected lysis responses. Anti-NKG2D and anti-2B4 also stimulated redirected cytotoxicity by TALL-104. By contrast, anti-NKG2A mAb did not stain the cells or inhibit killing responses. Alternatively, KIR3DL2 was detected on TALL-104, and expression of its reported ligand, human leukocyte antigen (HLA)-A, on target cells provided protection from cytotoxicity. Thus, NKp46, NKG2D, and 2B4 are activating receptors, and KIR3DL2 is an inhibitory receptor on TALL-104. The data demonstrate the ability of TALL-104 cells to recognize a wide variety of tumors with NK cell receptors and kill them with a broad arsenal of cytolytic effector mechanisms, including cytolytic granules and TNF family ligands.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937142     DOI: 10.1189/jlb.0604360

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  8 in total

1.  NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease.

Authors:  Nobuyoshi Hanaoka; Bana Jabri; Zhenpeng Dai; Cezary Ciszewski; Anne M Stevens; Cassian Yee; Hideki Nakakuma; Thomas Spies; Veronika Groh
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  CD8 T cells utilize TRAIL to control influenza virus infection.

Authors:  Erik L Brincks; Arna Katewa; Tamara A Kucaba; Thomas S Griffith; Kevin L Legge
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

3.  HLA-F and MHC class I open conformers are ligands for NK cell Ig-like receptors.

Authors:  Jodie P Goodridge; Aura Burian; Ni Lee; Daniel E Geraghty
Journal:  J Immunol       Date:  2013-09-09       Impact factor: 5.422

4.  New perspectives on the ligands and function of the killer cell immunoglobulin-like receptor KIR3DL2 in health and disease.

Authors:  Jacqueline Shaw; Simon Kollnberger
Journal:  Front Immunol       Date:  2012-11-16       Impact factor: 7.561

5.  The hemagglutinin-neuramidinase protein of Newcastle disease virus upregulates expression of the TRAIL gene in murine natural killer cells through the activation of Syk and NF-κB.

Authors:  Ying Liang; De-Zhi Song; Shuang Liang; Zeng-Feng Zhang; Ling-Xi Gao; Xiao-Hui Fan
Journal:  PLoS One       Date:  2017-06-14       Impact factor: 3.240

6.  Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.

Authors:  Mohammad Hashemi; Aliakbar Fazaeli; Saeid Ghavami; Ebrahim Eskandari-Nasab; Farshid Arbabi; Mohammad Ali Mashhadi; Mohsen Taheri; Wiem Chaabane; Mayur V Jain; Marek J Łos
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

7.  NKG2A inhibits TH2 cell effector function in vitro.

Authors:  Robert J Freishtat; Bahar Mojgani; Maryam Nazemzadeh; Kanneboyina Nagaraju; Eric P Hoffman
Journal:  BMC Pulm Med       Date:  2007-10-10       Impact factor: 3.317

8.  PBRM1 and the glycosylphosphatidylinositol biosynthetic pathway promote tumor killing mediated by MHC-unrestricted cytotoxic lymphocytes.

Authors:  Bridget L Menasche; Eric M Davis; Shifeng Wang; Yan Ouyang; Suzhao Li; Haijia Yu; Jingshi Shen
Journal:  Sci Adv       Date:  2020-11-27       Impact factor: 14.136

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.